{"url_path":"/sec/eldn/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221702-index.html","accession_number":"0001193125-26-221702","cik":"0001404281","ticker":"ELDN","issuer_name":"Eledon Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221702-index.html","primary_entity_key":"0001404281","primary_entity_name":"Eledon Pharmaceuticals, Inc."},"word_count":703,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n \n\n \n\n \n\n3.1\n\n \n\n[Restated Certificate of Incorporation of Novus Therapeutics, Inc., a Delaware corporation, dated September 22, 2014 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on September 26, 2014)](https://www.sec.gov/Archives/edgar/data/1404281/000119312514354857/d793658dex31.htm).\n\n \n\n \n\n \n\n3.2\n\n \n\n[Certificate of Amendment to Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a reverse stock-split), filed with the Secretary of the State of Delaware on May 9, 2017 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on May 15, 2017).](https://www.sec.gov/Archives/edgar/data/1404281/000119312517170677/d393884dex31.htm)\n\n \n\n \n\n \n\n3.3\n\n \n\n[Certificate of Amendment to Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a change in the corporation’s name to “Novus Therapeutics, Inc.”), filed with the Secretary of the State of Delaware on May 9, 2017 (filed with the SEC as Exhibit 3.2 on the Company’s Current Report on Form 8-K filed on May 15, 2017).](https://www.sec.gov/Archives/edgar/data/1404281/000119312517170677/d393884dex32.htm)\n\n \n\n \n\n \n\n3.4\n\n \n\n[Certificate of Amendment to the Restated Certificate of Incorporation of Novus Therapeutics, Inc., (effecting, among other things a reverse stock-split) effective as of October 5, 2020 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on October 6, 2020).](https://www.sec.gov/Archives/edgar/data/1404281/000119312520264806/d18987dex31.htm)\n\n \n\n \n\n \n\n3.5\n\n \n\n[Certificate of Amendment to the Restated Certificate of Incorporation of Novus Therapeutics, Inc., (effecting, among other things a change in the corporation’s name to “Eledon Pharmaceuticals, Inc.”) effective as of January 5, 2021 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on January 5, 2021)](https://www.sec.gov/Archives/edgar/data/1404281/000110465921000921/tm211620d1_ex3-1.htm).\n\n \n\n \n\n \n\n3.6\n\n \n\n \n\n[Certificate of Amendment to the Restated Certificate of Incorporation, as amended, of Eledon Pharmaceuticals, Inc., (effecting an increase in authorized shares of common stock) effective June 10, 2025 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on June 12, 2025).](https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/eldn-ex3_1.htm)\n\n \n\n \n\n \n\n3.7\n\n \n\n \n\n[Certificate of Amendment to the Restated Certificate of Incorporation, as amended, of Eledon Pharmaceuticals, Inc., (providing for exculpation of certain officers) effective June 10, 2025 (filed with the SEC as Exhibit 3.2 on the Company’s Current Report on Form 8-K filed on June 12, 2025).](https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/eldn-ex3_2.htm)\n\n \n\n \n\n \n\n3.8\n\n \n\n[Certificate of Designations of Series X Convertible Preferred Stock (filed with the SEC as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on February 19, 2020).](https://www.sec.gov/Archives/edgar/data/1404281/000119312520041903/d888744dex31.htm)\n\n \n\n \n\n \n\n3.9\n\n \n\n[Certificate of Designations of Series X1 Convertible Preferred Stock (filed with the SEC as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on September 15, 2020).](https://www.sec.gov/Archives/edgar/data/1404281/000119312520246314/d26397dex31.htm)\n\n \n\n \n\n \n\n3.10\n\n \n\n[Amended and Restated Bylaws of Eledon Pharmaceuticals, Inc. (filed with the SEC as Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on January 5, 2021).](https://www.sec.gov/Archives/edgar/data/1404281/000110465921000921/tm211620d1_ex3-2.htm)\n\n \n\n \n\n \n\n4.1\n\n \n\n[Form of Exchange Warrant (filed with the SEC as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on January 2, 2026).](https://www.sec.gov/Archives/edgar/data/1404281/000119312526000968/eldn-20251230.htm)\n\n \n\n \n\n \n\n31.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](eldn-ex31_1.htm)\n\n \n\n \n\n \n\n31.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](eldn-ex31_2.htm)\n\n \n\n \n\n \n\n  32.1**\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](eldn-ex32_1.htm)\n\n \n\n \n\n \n\n  32.2**\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](eldn-ex32_2.htm)\n\n \n\n \n\n \n\n101.INS\n\n \n\nINLINE XBRL Instance Document– the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\n \n\n \n\n \n\n101.SCH\n\n \n\nINLINE XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n104\n\n \n\nCover Page formatted as INLINE XBRL and contained in Exhibit 101\n\n \n\n*\n\n \n\nFiled herewith.\n\n**\n\n \n\nFurnished herewith.\n\n \n\n63\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nEledon Pharmaceuticals, Inc.\n\n \n\n \n\n \n\n \n\n \n\nDate: May 13, 2026\n\n \n\nBy:\n\n \n\n/s/ David-Alexandre C. Gros, M.D.\n\n \n\n \n\n \n\n \n\nDavid-Alexandre C. Gros, M.D.\n\n \n\n \n\n \n\n \n\nChief Executive Officer\n\n and Director (Principal\n\nExecutive Officer)\n\nDate: May 13, 2026\n\n \n\nBy:\n\n \n\n/s/ Paul Little\n\n \n\n \n\n \n\n \n\nPaul Little\n\n \n\n \n\n \n\n \n\nChief Financial Officer\n\n(Principal Financial Officer)\n\n64"}